131 related articles for article (PubMed ID: 21628603)
1. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
Jansat JM; Lamarca R; Garcia Gil E; Ferrer P
Int J Clin Pharmacol Ther; 2009 Jul; 47(7):460-8. PubMed ID: 19640353
[TBL] [Abstract][Full Text] [Related]
5. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
[TBL] [Abstract][Full Text] [Related]
6. Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.
Ortiz S; Flach S; Ho J; Li F; Caracta CF; Gil EG; Jansat JM
Biopharm Drug Dispos; 2012 Jan; 33(1):39-45. PubMed ID: 22275272
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.
Schmid K; Pascual S; Gil EG; Ortiz S; Jansat JM
Clin Ther; 2010 Sep; 32(10):1798-812. PubMed ID: 21194604
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.
de la Motte S; Beier J; Schmid K; Pascual S; Jansat JM; Gil EG
Int J Clin Pharmacol Ther; 2012 Jun; 50(6):403-12. PubMed ID: 22541745
[TBL] [Abstract][Full Text] [Related]
9. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
Maltais F; Milot J
Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
[TBL] [Abstract][Full Text] [Related]
10. The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.
Li W; Daoud SZ; Trivedi R; Lukka PB; Jimenez E; Molins E; Stewart C; Bharali P; Garcia-Gil E
Int J Chron Obstruct Pulmon Dis; 2023; 18():2725-2735. PubMed ID: 38046981
[TBL] [Abstract][Full Text] [Related]
11. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects.
Lasseter KC; Aubets J; Chuecos F; Gil EG
J Clin Pharmacol; 2011 Jun; 51(6):923-32. PubMed ID: 20959525
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
13. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
Gelb AF; Tashkin DP; Make BJ; Zhong X; Garcia Gil E; Caracta C;
Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
[TBL] [Abstract][Full Text] [Related]
15. An update on the efficacy and safety of aclidinium bromide in patients with COPD.
Alagha K; Bourdin A; Tummino C; Chanez P
Ther Adv Respir Dis; 2011 Feb; 5(1):19-28. PubMed ID: 20884687
[TBL] [Abstract][Full Text] [Related]
16. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
17. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
Jones P
Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509
[TBL] [Abstract][Full Text] [Related]
18. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.
Sentellas S; Ramos I; Albertí J; Salvà M; Antón F; Miralpeix M; Beleta J; Gavaldà A
Eur J Pharm Sci; 2010 Mar; 39(5):283-90. PubMed ID: 20093184
[TBL] [Abstract][Full Text] [Related]
19. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD.
Marth K; Schuller E; Pohl W
Respir Med; 2015 May; 109(5):616-24. PubMed ID: 25796962
[TBL] [Abstract][Full Text] [Related]
20. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.
Cazzola M
Curr Opin Investig Drugs; 2009 May; 10(5):482-90. PubMed ID: 19431081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
